A “global first” anti-tumor vaccine was unveiled by Guangzhou Phar. Holdings in the recent Guangzhou International Investment Conference. Having applied 8 invention patents, this anti-tumor vaccine is proved to be safe and effective to multiple tumors, including ovarian cancer, malignant melanoma and etc.
Taking 10 years’ efforts, the anti-tumor vaccine was jointly developed with experts from Europe, America and Australia, with a investment of 329billion RMB from Chinese government.
“Technologies are mature to industrialize the vaccine now and will reach target output in 3 years,” said Li Mingsong, vice-manager of the subsidiary company established by Guangzhou Phar. Holdings for the anti-tumor project.”
“Great demands for safe and effective anti-tumor vaccine are showing up as tumor continuously peaks among people,” said Li Mingsong, “our vaccine is original worldwide and expected to fill the gap of this field in China.”
Dr.Shuki Gleitman, president of Guangzhou Sino-Israel Bio-Industry Investment Fund, presented in the seminar organized by Guangzhou Phar. Holdings in the Guangzhou International Investment Conference. [Photo\Newsgd.com]
Besides, Guangzhou Phar. Holdings also cooperates with BayBio Alliance, CABS Alliance and high-education institutes as Stanford University and UCSF to introduce high-end technologies and talents from America’s Silicon Valley area.
“We plan to double our sales revenue to 150 billion yuan and become one of the Global 500 by 2020,”said Li Chuyuan, present of Guangzhou Phar. Holdings.